Claims for Patent: 7,807,798

Summary for Patent: 7,807,798

Title:	Human monoclonal antibodies to epidermal growth factor receptor
Abstract:	In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control.
Inventor(s):	Jakobovits; Aya (Menlo park, CA), Yang; Xiao-Dong (Palo Alto, CA), Gallo; Michael (San Jose, CA), Jia; Xiao-Chi (San Mateo, CA)
Assignee:	Amgen Fremont Inc. (Fremont, CA)
Application Number:	11/267,860
Patent Claims:	1. An isolated human antibody that binds to human epidermal growth factor receptor (EGF-r), comprising: a) a heavy chain immunoglobulin molecule comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 17; and b) a light chain immunoglobulin molecule comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 18; wherein the antibody specifically binds to EGF-r. 2. The antibody of claim 1, wherein the heavy chain immunoglobulin molecule comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 17. 3. The antibody of claim 1 or claim 2, wherein the light chain immunoglobulin molecule comprises an amino acid sequence having at least 99% sequence identity to the amino acid sequence encoded by the nucleotide sequence set forth in SEQ ID NO: 18. 4. The antibody of claim 1, wherein the heavy chain immunoglobulin molecule comprises the amino acid sequence set forth in SEQ ID NO: 76. 5. The antibody of claim 1 or claim 4, wherein the light chain immunoglobulin molecule comprises an amino acid sequence set forth in SEQ ID NO: 54. 6. An isolated human antibody comprising a heavy chain immunoglobulin molecule comprising amino acids 8 to 85 of SEQ ID NO: 76, and comprising a light chain immunoglobulin molecule comprising amino acids 5 to 78 of SEQ ID NO: 54, wherein the antibody specifically binds to EGF-r. 7. An isolated human antibody comprising a heavy chain immunoglobulin molecule comprising: a) a CDR1 comprising amino acids 8 to 15 of SEQ ID NO: 76; b) a CDR2 comprising amino acids 29 to 45 of SEQ ID NO: 76; and c) a CDR3 comprising amino acids 77 to 85 of SEQ ID NO: 76; and comprising a light chain immunoglobulin molecule comprising: d) a CDR1 comprising amino acids 5 to 15 of SEQ ID NO: 54; e) a CDR2 comprising amino acids 31 to 37 of SEQ ID NO: 54; and f) a CDR3 comprising amino acids 70 to 78 of SEQ ID NO: 54; wherein the antibody specifically binds to EGF-r. 8. An isolated human antibody comprising a heavy chain immunoglobulin molecule comprising the amino acid sequence of SEQ ID NO: 76, and a light chain immunoglobulin molecule comprising the amino acid sequence of SEQ ID NO: 54. 9. The antibody of any one of claims 1, 6, 7 and 8, wherein the antibody is a binding fragment. 10. The antibody of any one of claims 1, 6, 7 and 8, wherein the antibody is an IgG2 antibody. 11. The antibody of any one of claims 1, 6, 7 and 8, wherein the antibody specifically binds EGF-r with a dissociation constant of less than or equal to 10 nM.

Details for Patent 7,807,798

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2017-05-05

International Patent Family for US Patent 7,807,798

Country	Patent Number	Estimated Expiration
Austria	366747
Australia	2004231235
Australia	4063902
Australia	7287098
Australia	777918
Canada	2288962
Germany	122008000009